Clinical trials: Metastatic Cutaneous Melanoma
Unresectable or Metastatic Melanoma
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
This was a Phase 1, open-label, non-randomized study of the combination of NY-ESO-1 plus ipilimumab in patients with unresectable or metastatic melanoma for whom treatment with ipilimumab was indicated.
- Trial name
- NCT01810016
- Testing
- Ipilimumab, NY-ESO-1 Protein Vaccine, NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide
- Where
- 5 sites in United States, Australia
- Volunteers
- 8 people
- Sponsor
- Ludwig Institute for Cancer Research
Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors
RATIONALE: Interferon gamma may interfere with the growth of cancer cells and may be an effective treatment for melanoma and solid tumors.
- Trial name
- NCT00004016
- Testing
- recombinant interferon gamma
- Where
- United States
- Sponsor
- University of Rochester
Stage IV Melanoma, Recurrent Melanoma
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00019448
- Testing
- gp100 antigen, interleukin-2
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma
ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
With the introduction of checkpoint inhibitors substantial improvements have been made in the treatment of malignant melanoma (MM). Despite this still a a subset of patients, approximately 50 %, experience no response to therapy.
- Trial name
- NCT04904185
- Testing
- Cyclophosphamide, Fludarabine Phosphate, Multiple Antigen Specific Endogenously derived T cells
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- Inge Marie Svane
Stage IV Melanoma
Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients
This study will test whether immune functions in individual cancer patients can be characterized in a quantitative manner using new technologies that analyze nucleic acids from peripheral blood cells and whether those…
- Trial name
- NCT02744209
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Melanoma
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in…
- Trial name
- RELATIVITY-127 (NCT05625399)
- Testing
- Nivolumab + Relatlimab, rHuPH20
- Where
- 149 sites in United States, Australia and 17 more
- Volunteers
- 579 people
- Sponsor
- Bristol-Myers Squibb
Central Nervous System Neoplasms, Neoplasm Metastasis
Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy
The goal of this study is to find the maximum dose of a drug, temozolomide, that can safely be given to subjects with brain tumors. Past studies showed that the maximum dose of temozolomide was limited by low blood counts.
- Trial name
- CN-306 (NCT00629187)
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Tufts Medical Center
Melanoma
A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma
This Phase II, multicenter, randomized, double-blind, placebo-controlled trial was designed to estimate the efficacy and characterize the safety of bevacizumab when combined with carboplatin + paclitaxel chemotherapy compared…
- Trial name
- BEAM (NCT00434252)
- Testing
- bevacizumab, carboplatin, paclitaxel
- Volunteers
- 214 people
- Sponsor
- Genentech, Inc.
Metastatic Melanoma
Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox
This is an open-label, clinical efficacy study of Ipilimumab in patients with Stage IIIC and Stage IV melanoma who have recently been treated with Denileukin Diftitox.
- Trial name
- NCT02009384
- Testing
- Ipilimumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Louisville
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Melanoma (Skin)
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma
RATIONALE: Monoclonal antibodies, such as ticilimumab (CP-675,206), can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00471887
- Testing
- CP-675,206
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Acral Lentiginous Malignant Melanoma, Recurrent Melanoma
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
This phase II trial is studying how well imatinib mesylate works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.
- Conditions
- Acral Lentiginous Malignant Melanoma, Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma
- Trial name
- NCT00470470
- Testing
- imatinib mesylate, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Cutaneous Malignant Melanoma
Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma
This is a multicenter, randomized, double-blind, placebo-controlled phase I/II trial designed to characterize the safety and estimate the efficacy of nintedanib when combined with paclitaxel chemotherapy compared with paclitaxel…
- Trial name
- NIPAWILMA (NCT02308553)
- Testing
- Nintedanib, Paclitaxel
- Where
- 10 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Prof. Dr. med. Dirk Schadendorf
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal
RATIONALE: Vaccines made from a person's white blood cells and melanoma cells may make the body build an immune response and kill the tumor cells.
- Trial name
- NCT00003229
- Testing
- aldesleukin, gp100 antigen, tyrosinase peptide
- Where
- 2 sites in United States
- Sponsor
- Duke University
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
This phase I/IIa trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens…
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma
- Trial name
- NCT02650986
- Testing
- Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Melanoma
Intratumoral Injections of LL37 for Melanoma
The goal of this clinical research study is to find the appropriate dose of LL37 that can be given to patients with melanoma. Researchers also want to learn if LL37 can stimulate the immune system to help control the disease.
- Trial name
- NCT02225366
- Testing
- LL37, Photographs
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Melanoma
A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma
A phase I clinical study evaluating LBL-007 in the treatment of subjects with advanced solid tumors
- Trial name
- NCT04640545
- Testing
- LBL-007, Toripalimab, Axitinib Tablets
- Where
- 7 sites in China
- Volunteers
- 79 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Melanoma
Safety of TKI258 in Advanced/Metastatic Melanoma Subjects
This study is an open-label, dose-escalating study to delineate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TKI258. Pharmacokinetics and pharmacodynamics will be performed on all subjects.
- Trial name
- NCT00303251
- Testing
- TKI258
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma (Skin)
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
RATIONALE: Peginterferon (PEG-interferon) alfa-2b may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have stage…
- Trial name
- NCT00049530
- Testing
- PEG-interferon alfa-2b
- Where
- 32 sites in United States
- Volunteers
- 32 people
- Sponsor
- Eastern Cooperative Oncology Group
Uveal Melanoma
Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)
Prospective, open labelled, monocentric trial to evaluation of the circulating tumor DNA rate in the blood, before and after curative resection of hepatic metastasis of uveal melanoma (HMUM) and during post-surgery follow-up
- Trial name
- ctDNA R0 (NCT02849145)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Institut Curie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.